Colorectal Cancer

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response, which is highly correlated with overall survival, was improved for patients with metastatic colorectal cancer who added selective internal radiation therapy (SIRT) to chemotherapy.

The addition of cetuximab to standard FOLFOX-4 chemotherapy in the first-line treatment of patients with RAS wild-type metastatic colorectal cancer significantly improved survival outcomes.

MABp1, a novel anti–interleukin 1-alpha antibody, was safe, well-tolerated, and demonstrated a significant impact on symptoms compared with placebo for patients with advanced colorectal cancer.

Adding selective internal radiation therapy with SIR-Spheres Y-90 resin microspheres to standard first-line chemotherapy significantly increased hepatic depth of response in patients with metastatic colorectal cancer.

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses the significance and benefits of the Cologuard screening test for colorectal cancer.

Daniel Sargent, PhD, professor of Oncology and Biostatistics, Mayo Clinic in Rochester, Minnesota, discusses the IDEA initiative, which is an international study to examine if patients with colon cancer would benefit from reducing the duration of adjuvant therapy from 3 months to 6 months to reduce side effects and cost.

Combined inhibition of the PD-L1/PD-1 axis with atezolizumab (Tecentriq) and the MEK pathway with cobimetinib (Cotellic) showed promising clinical activity and a good safety profile in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.

Kanwal Raghav, MBBS, MD, assistant professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining HER2 gene amplification in patients with metastatic colorectal cancer.

Michael J. Overman, MD, discusses the findings of the phase II CheckMate-142 study, which examined nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with high microsatellite instability colorectal cancer.

The United States Preventative Services Task Force recommends screening for colorectal cancer using traditional colonoscopy or one of 7 tests at various frequencies for all patients aged 50 to 75.

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses a study examining nivolumab (Opdivo) monotherapy, ipilimumab (Yervoy) monotherapy, and the combination of nivolumab and ipilimumab in patients with high microsatellite instability metastatic colorectal cancer.

In patients with advanced colorectal cancer, the combination regimen of cobimetinib (Cotellic) and atezolizumab (Tecentriq) was found to demonstrate clinical activity as well as have a good safety profile.

Results of an analysis presented at the 2016 ASCO Annual Meeting demonstrate the difficulty in determining the prevalence of germline cancer susceptibility gene mutations in patients with colorectal cancer (CRC) who do not harbor Lynch syndrome.

Nivolumab (Opdivo) as a monotherapy and in combination with ipilimumab (Yervoy) demonstrated promising antitumor activity in patients with high microsatellite instability (MSI-H) metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, discusses the use of both regorafenib and TAS-102, as well as the potential role immunotherapy could have within colorectal cancer.

Precancerous colon polyps exhibit many of the same driver mutations that fuel the development of colorectal cancer.

Survival outcomes in patients with metastatic colorectal cancer were significantly longer among those with tumors originating on the left versus the right side of the colon, according to a retrospective analysis of the phase III 80405 trial.

Navesh K. Sharma, DO, PhD, discusses findings on a study looking at the addition of Yttrium-90 resin microspheres to standard frontline FOLFOX-based chemotherapy with or without bevacizumab in liver metastatic colorectal cancer.

Given the numerous available treatment options, the most important issue in frontline colorectal cancer care is clarifying the goals of therapy.

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses about 2 agents, regorafenib and TAS-102, for the treatment of patients with treat colorectal cancer.

Raju Kucherlapati, PhD, serves as principal investigator of a Genome Characterization Center as part of The Cancer Genome Atlas program, a National Cancer Institute initiative aimed at defining the copy number changes and structural aberrations present in many different cancer types.

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses a study demonstrating the benefit of utilization of the Cologuard screening test for colorectal cancer (CRC).